Search results

The final master's thesis analyzes the competitiveness of Lithuanian pharmaceutical industry. The most pressing problems facing the sector in the pharmaceutical industry are highlighted. Based on the analysis of statistical data, it can be stated that the Lithuanian pharmaceutical sector is one of the most legally regulated economic sectors. It is relatively small - the sector is dominated by companies of different sizes producing pharmaceutical products of different values. The performance of companies varies greatly, and the development of the sector is volatile and depends on the performance of large, multinational companies. It is also noticeable that industrial enterprises are mainly focused on foreign markets - most of the products of the Lithuanian pharmaceutical industry are exported and export values are growing every year. The main weaknesses of the sector are insufficient investment in R&D activities: in the development of new products, patent development and innovations compared to other European Union countries. Also, the Lithuanian pharmaceutical industry does not respond sufficiently to the needs of consumers in the domestic market and the increased demand for pharmaceutical products, especially during the COVID-19 pandemic. The analysis shows that Lithuania and the European Union pay great attention to the development of the life sciences sector, including the pharmaceutical industry, and companies are encouraged to use financial support or expert advice and consultations to increase industrial competitiveness globally: through R&D activities, cooperation with higher education institutions, innovation development, modernizing or expanding infrastructure, increasing exports or improving the quality assurance system. Also, those companies involved in the development and production of innovative products, especially biotechnological pharmaceuticals with the greatest potential, have a greater competitive advantage.

The final master's thesis analyzes the competitiveness of Lithuanian pharmaceutical industry. The most pressing problems facing the sector in the pharmaceutical industry are highlighted. Based on the analysis of statistical data, it can be stated that the Lithuanian pharmaceutical sector is one of the most legally regulated economic sectors. It is relatively small - the sector is dominated by companies of different sizes producing pharmaceutical products of different values. The performance of companies varies greatly, and the development of the sector is volatile and depends on the performance of large, multinational companies. It is also noticeable that industrial enterprises are mainly focused on foreign markets - most of the products of the Lithuanian pharmaceutical industry are exported and export values are growing every year. The main weaknesses of the sector are insufficient investment in R&D activities: in the development of new products, patent development and innovations compared to other European Union countries. Also, the Lithuanian pharmaceutical industry does not respond sufficiently to the needs of consumers in the domestic market and the increased demand for pharmaceutical products, especially during the COVID-19 pandemic. The analysis shows that Lithuania and the European Union pay great attention to the development of the life sciences sector, including the pharmaceutical industry, and companies are encouraged to use financial support or expert advice and consultations to increase industrial competitiveness globally: through R&D activities, cooperation with higher education institutions, innovation development, modernizing or expanding infrastructure, increasing exports or improving the quality assurance system. Also, those companies involved in the development and production of innovative products, especially biotechnological pharmaceuticals with the greatest potential, have a greater competitive advantage.